📢 Join us for a webinar on improving HPB surgery outcomes: Optimizing Patient Outcomes with Brian Goh 🗓️ Tuesday 1 July | 🕐 13:00 BST. Learn about the VIBe scale and bleeding management Presented with IHPBA corporate partner Baxter 🔗 Register here: bit.ly/VIBeScaleWebinar
🎓 International HPB Surgery School – Session 2
📅 June 18, 2025 | 🕕 18:00–21:00 (CET)
Topics: Liver pathology, physiology & regeneration
📺 Live and reply at: 🌐 school.hpb.org.tr#HPBSurgery#EAHPBA#IHPBA#TurkHPB
Important prospective data on NECarcinoma & G3-NET from NORDIC NEC2 🇩🇰🇳🇴🇸🇪
With chemo💉💊
▪️Median survival 7m NEC
▫️Immediate progression 41% NEC
▪️G3-NET do better, esp Ki67 <55%
⚠️Caution! NEC aggressive - need better systemic Rx
🔗 nature.com/articles/s41416-0…
يسر الجمعية السعودية لأمراض وزراعة الكبد أن تستقبل الأبحاث والدراسات العلمية المتعلقة بأمراض و زراعة الكبد للمؤتمر السنوي المنعقد في 16-18 أكتوبر 2025
مع التنويه أن آخر يوم لتسليم الأبحاث في 1 سبتمبر 2025
SASLT is pleased to receive your abstracts on Liver Diseases and Transplantation ahead of our annual conference on 16-18 October 2025.
Don’t miss the chance to showcase your work. Kindly submit your abstract by
September 1, 2025!
Link:
forms.gle/QZVgUowpEEzw9wPC9#LiverDisease#SASLT2025
📢 More Brilliant Minds Join the Stage! Meet the next three speakers who will share their expertise at the 𝐆𝐮𝐥𝐟 𝐇𝐏𝐁 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞.
📅18-19 April 2025
📍Novotel Abu Dhabi Al Bustan
🔗buff.ly/mjGwUc7#Hepatopancreatobiliary#livercare
October is Liver Cancer Awareness Month! Let’s join together to raise awareness for cholangiocarcinoma, the second most common liver cancer worldwide. Awareness is the first step toward prevention and finding a cure.
Learn more about #cholangiocarcinoma and how you can help at curecca.org.
📢 Calling all HPB surgeons and fellows! 🌍 Your voice matters in shaping the future of HPB training. Complete the ⭐️Survey on Accreditation of HPB-Centres and Fellowship ⭐️now!
Share your thoughts with us.
#HPBSurgery#FellowshipTrainingdocs.google.com/forms/d/e/1F…
Surgery vs ablation for small-size CRC liver mtes at #ASCO24
🔎COLLISION phase III, 300 pts
👉medien size 14mm, 2mets
👉mOS: no difference
👉similar local control
👉reduced morbidity & mortality in ablation arm
🧐Ablation very valid option
@myESMO@ILCAnews@EASLnews#livertwitter
Tumor debulking to first-line CTx for patients with multiorgan metastatic colorectal cancer #ASCO24
🔎ORCHESTRA phase III, 382 pts
👉10 yr accrual
👉mPFS: 10.4 vs 10.5 mo
👉mOS: 27.5 vs 30 mo, HR: 0.88
🧐Tumor debulking does not make sense
@myESMO
Leaving #CapeTown#IHPBA2024 with mixed feelings.Caught up with old friends and made new ones.
New Ideas & prospectives are on the way. #DEI#ECG and #HPbBridge were on the highlights. Looking forward to catching up with you all in #Dublin next year.@IHPBA@EAHPBA